Fulvestrant 250mg/5mL Injection$174.00
1–9 boxes
$174.00 each
10–24 boxes
8% off
25+ boxes
10% off
Fulvestrant 250mg/5mL Injection
SKU GME1127Oncology Care
Product Introduction
Fulvestrant 250mg/5mL is an endocrine treatment for hormone receptor-positive advanced breast cancer. It is used alone or with an appropriate targeted medicine according to menopausal status, tumour features and previous endocrine treatment.
How to use
A healthcare professional gives the medicine slowly by deep intramuscular injection into the buttock. A standard 500mg treatment visit uses two 250mg injections, one into each buttock, with extra loading visits early in treatment before monthly maintenance. Liver impairment can change the dose.
How it works
Fulvestrant binds oestrogen receptors and promotes their breakdown. Removing these receptors reduces the signals that oestrogen can deliver to hormone-dependent cancer cells.
Side effects
Injection-site discomfort, hot flushes, nausea, fatigue, joint pain and liver-test changes can occur. Significant bleeding or nerve injury at the injection site is uncommon. Persistent numbness, weakness or radiating leg pain after injection needs assessment.
Important information
Anticoagulant use, a bleeding disorder, low platelets and liver disease affect injection planning. Premenopausal patients receiving suitable combination treatment also need ovarian suppression. Pregnancy and breastfeeding are avoided because endocrine blockade can harm a developing baby.
Uses
- HR-positive advanced or metastatic breast cancer in appropriate endocrine monotherapy or targeted-combination regimens.
Benefits
Oestrogen-receptor degradation offers disease control when hormone signalling remains a treatment target, including after some previous endocrine therapies. It can be combined with targeted agents to extend tumour control in suitable patients.
Why might I receive two injections at one visit?
Each 5mL presentation contains 250mg. A 500mg dose therefore uses two separate injections rather than doubling the volume into one buttock.
Does fulvestrant lower oestrogen production like an aromatase inhibitor?
Its main action is different: it blocks and removes oestrogen receptors. Aromatase inhibitors primarily reduce oestrogen production.
Why are the first appointments closer together?
Loading visits establish the desired exposure sooner. Once this initial schedule is complete, treatment usually moves to a monthly interval.
Can a premenopausal patient use this without ovarian suppression?
In appropriate regimens, ovarian suppression is added because functioning ovaries continue to produce oestrogen. Menopausal status is therefore part of treatment selection.
SERD: selective oestrogen receptor degrader. HR-positive: tumour expressing hormone receptors. Endocrine therapy: treatment targeting hormone-driven cancer growth. Loading schedule: extra early doses establishing exposure. Intramuscular: into a muscle.; AR: Fulvestrant 250mg/5mL حقن; FR: Fulvestrant 250mg/5mL préparation injectable; PT: Fulvestrant 250mg/5mL injetável; ES: Fulvestrant 250mg/5mL inyectable; RU: Fulvestrant 250mg/5mL инъекционная форма; ID: Fulvestrant 250mg/5mL injeksi; VI: Fulvestrant 250mg/5mL thuốc tiêm; MS: Fulvestrant 250mg/5mL suntikan; TL: Fulvestrant 250mg/5mL iniksyon; ZH-SG: Fulvestrant 250mg/5mL 注射剂